Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Health
  • Book Release
  • Business
  • Financial
ncarol.com

'Spot Detective' – Check your spots this summer
ncarol.com/10200678

Trending...
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
The Spot Detective - who are they The Spot Detective - freckle
The latest campaign urging Australians to get their skin checked

MELBOURNE, Australia & SYDNEY - ncarol.com -- OncoBeta, a leading medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancer, has launched The Spot Detective campaign to rally Australians in the fight against skin cancer this summer.

With two out of three Australians diagnosed with skin cancer before the age of 701, it is vital for all Australians to have regular skin checks. The Spot Detective campaign is encouraging Australians to visit a Spot Detective – their GP, dermatologist or skin health specialist – to have their spots assessed and to learn about the various treatments available for those diagnosed with non-melanoma skin cancer.

Skin cancer occurs when skin cells are damaged, often from overexposure to ultraviolet (UV) radiation from the sun. There are three main types of skin cancer: basal cell carcinoma (BCC); squamous cell carcinoma (SCC) and melanoma.2 Australia has one of the highest melanoma rates in the world1, with one Australian dying from melanoma every six hours.3 A skin check can save your life.

OncoBeta's Australian Medical Director, Dr Sam Vohra, says, "Thankfully most skin cancers are treatable and most of us will know someone who has had a skin cancer. Today, there are a range of treatments available to patients in addition to surgery, some of which are painless*, only needing a single session† and non-invasive."4-6

The Spot Detective campaign is asking Australians to take action: if they see a skin spot that is suspicious, new, oddly shaped or has changed in colour then it's time to get it checked. The campaign includes a series of LIVE reads across 2GB and WSFM in Sydney and 3AW and Gold 104.3 in Melbourne, as well as a social media and digital marketing campaign, and free skin check pop-ups at various locations.

More on ncarol.com
  • Detroit Roots, Film Scores and Python Shape KayeDinero's Asheville Sound
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off

"With one of the highest incidences of skin cancer in the world, Australians need to be vigilant with their skin. The Spot Detective campaign is a timely reminder to make sure you are protecting yourself from the sun, and if you notice any changes to your skin, check in with a skin health specialist," added Dr Vohra.

Another health initiative from OncoBeta, this public awareness campaign also encourages anyone diagnosed with non-melanoma skin cancer to be well informed about all treatments and discuss their most suitable options with a healthcare professional. OncoBeta's skin cancer therapy which utilises the rhenium-188 isotope is now available at private clinics at Melbourne and Sydney. Patients with difficult anatomic localisations of a tumour, such as the ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery, may benefit from this non-invasive solution.

To find out more information on skin cancer, and to learn what treatments are available, visit: www.spotdetective.com.au

About OncoBeta® GmbH
OncoBeta® GmbH, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

More on ncarol.com
  • Fashion vs. Fascism - Because Democracy Should Always Be In Style
  • From Degrassi to Cass Tech: The Unexpected Influences Behind Asheville's KayeDinero
  • Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
  • KayeDinero Takes "Appalachia" Above the Blue Ridge With New Aerial Music Visual
  • Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain.3
†
Complete tumour regression in 98.5% of lesions treated.

References:
1. Cancer Council. Understanding Skin Cancer. January 2020. https://www.cancercouncil.com.au/ (accessed October 2022).
2. Skin Cancer. Available at https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605 [Accessed October 2022]
3. Melanoma Institute Australia. Melamoma Facts. https://melanoma.org.au/about-melanoma/melanoma-facts/ (accessed October 2022).
4. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48(5):1511–1521.
5. Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
6. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Google AI Says KayeDinero Isn't the Greatest Female Producer. She Asks: Who Decides?
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
  • From Michael Jackson to Drake: The Artists Who Shaped KayeDinero's Sound
  • L-Tron to Attend the 2026 NC, GA, TN, SC Joint Regional IAI Conference
  • "Kulture Metrics" Isn't Just an Album Title: KayeDinero Connects Music, Markets and Code
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pipeline Developer Isn't Just a Song: KayeDinero Builds Software, Markets and Music
  • Who Is KayeDinero? The Asheville Artist Also Builds Software and Trading Systems
  • Leaping Cat Creative Takes Shape Around the Problems Nobody Quite Owns
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • As Boone Takes Art to the Streets, KayeDinero Asks What Makes Creativity Human
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
  • As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
  • Why Did KayeDinero Put Haywood Road Into a Song?
_catLbl0 _catLbl1

Popular on ncarol.com

  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 160
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 157
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 141
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 133
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 123
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 123
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 122
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 121
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies - 115
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 112

Similar on ncarol.com

  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Piedmont Crossing Celebrates 40 Years of Caring, Community, and Connection
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute